Volume 41, Issue 2, Pages (February 2002)

Slides:

Advertisements

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 59, Issue 2, Pages (February 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 45, Issue 3, Pages (March 2004)

Volume 53, Issue 5, Pages (May 2008)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 69, Issue 1, Pages (January 2016)

Volume 61, Issue 2, Pages (February 2012)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

High Dose Rate Brachytherapy of Localized Prostate Cancer

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Obesity and Prostate Cancer: A Role for Adipokines

Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? Bob Djavan European.

Shaheen Alanee, Kasmintan Schrader, Kenneth Offit European Urology

Counselling the Prostate Cancer Patient

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Molecular Tumour Profiling for Detection of Biomarkers in Renal Cell Tumours Kerstin Junker, Jimsgene Sanjmyatav, Joerg Mueller, Thomas Steiner, Heiko.

Human Papilloma Virus, Histopathological, and Molecular Subtyping in Penile Cancer: Relevance for Prognosis and Therapy Kerstin Junker, Sebastian Hölters,

Volume 53, Issue 2, Pages (February 2008)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Mark A. Rubin, Gabriele Girelli, Francesca Demichelis European Urology

Volume 66, Issue 2, Pages (August 2014)

Volume 63, Issue 3, Pages (March 2013)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Tillmann Loch, Pat Fox Fulgham European Urology

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,

Volume 4, Issue 1, Pages 4-6 (July 2003)

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Volume 69, Issue 5, Pages (May 2016)

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

Volume 66, Issue 6, Pages (December 2014)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

How and When to Take Prostate Biopsies

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Volume 56, Issue 4, Pages (October 1999)

Improving Flexibility and Quality of Life for Your Patients: A Must?

Volume 54, Issue 1, Pages (July 2008)

Volume 17, Issue 2, Pages (February 1950)

Familial amyloidosis: Great progress for an orphan disease

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Volume 53, Issue 6, Pages (June 2008)

Management of Prostate Cancer: Global Strategies

Volume 53, Issue 2, Pages (February 2008)

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Manfred Wirth, Peter Iversen, David McLeod, William See

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Volume 56, Issue 4, Pages (October 1999)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Epidemiology and Demographics of Prostatitis

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Does PSA Testing Influence the Natural History of Prostate Cancer?

Presentation transcript:

Volume 41, Issue 2, Pages 167-171 (February 2002) Gain in Chromosome 8q Correlates with Early Progression in Hormonal Treated Prostate Cancer Thomas Steiner, Kerstin Junker, Frank Burkhardt, Andreas Braunsdorf, Volker Janitzky, Joerg Schubert European Urology Volume 41, Issue 2, Pages 167-171 (February 2002) DOI: 10.1016/S0302-2838(01)00030-6

Fig. 1 Chromosomal aberrations in primary prostate biopsies; data are shown dependent on clinical course of disease. European Urology 2002 41, 167-171DOI: (10.1016/S0302-2838(01)00030-6)

Fig. 2 CGH Profiles showing multiple gains and losses of chromosome parts in a tumor with progression (patient no. 2): profile at the middle line: no changes; shift to the right borderline: gain of chromosome or part of a chromosome; shift to the left borderline: loss of chromosome or part of a chromosome. European Urology 2002 41, 167-171DOI: (10.1016/S0302-2838(01)00030-6)